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Abstract
Aims: As one of the five Lactate dehydrogenase (LDH) isoenzymes, LDH5 has the highest efficiency to catalyze 
pyruvate transformation to lactate. LDH5 overexpression in cancer cells induces an upregulated glycolytic metabolism 
and reduced dependence on the presence of oxygen. Here we analyzed LDH5 protein expression in a well 
characterized large cohort of primary lung cancers in correlation to clinico-pathological data and its possible impact 
on patient survival.
Methods: Primary lung cancers (n = 269) and non neoplastic lung tissue (n = 35) were tested for LDH5 expression by 
immunohistochemistry using a polyclonal LDH5 antibody (ab53010). The results of LDH5 expression were correlated to 
clinico-pathological data as well as to patient's survival. In addition, the results of the previously tested Transketolase 
like 1 protein (TKTL1) expression were correlated to LDH5 expression.
Results: 89.5% (n = 238) of NSCLC revealed LDH5 expression whereas LDH5 expression was not detected in non 
neoplastic lung tissues (n = 34) (p < 0.0001). LDH5 overexpression was associated with histological type 
(adenocarcinoma = 57%, squamous cell carcinoma = 45%, large cell carcinoma = 46%, p = 0.006). No significant 
correlation could be detected with regard to TNM-stage, grading or survival. A two sided correlation between the 
expression of TKTL1 and LDH5 could be shown (p = 0.002) within the overall cohort as well as for each grading and pN 
group. A significant correlation between LDH5 and TKTL1 within each histologic tumortype could not be revealed.
Conclusions: LDH5 is overexpressed in NSCLC and could hence serve as an additional marker for malignancy. 
Furthermore, LDH5 correlates positively with the prognostic marker TKTL1. Our results confirm a close link between the 
two metabolic enzymes and indicate an alteration in the glucose metabolism in the process of malignant 
transformation.
Introduction
As one of the five lactate dehydrogenase (LDH) isoen-
zymes, LDH5 has the highest efficiency to catalyze pyru-
vate transformation to lactate. LDH5 overexpression in
cancer cells induces an upregulated glycolytic metabo-
lism and reduced dependence on the presence of oxygen.
According to Warburg, malignant tumors generate lac-
tate even in the presence of sufficient oxygen supply
(Warburg effect) [1]. Upon this Thompson postulated a
shift from oxidative phosphorylation to anaerobic glycol-
ysis as a key element for malignant transformation of cells
[2]. This change in the cells' glucose metabolism is not
due to mitochondrial defects but results in a higher
capacity and efficiency to facilitate cellular growth, thus
to synthesize fatty acids, amino acids and reductive
equivalents necessary for nucleic acid synthesis. The gen-
eration and consumption of oxaloacetat - kata- and ana-
plerosis - within the citric acid cycle (TCA) is supposed
to play a key role in this phenomenon as intermediates of
the TCA are needed for fatty acid synthesis which in turn
are necessary for cell membrane composition [3,4]. Pyru-
vate as a precursor of acetyl-CoA is therefore a pivotal
substrate in tumor cell glycolysis [3,4].
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Nucleic acid synthesis is initiated via the pentose phos-
phate pathway (PPP) which also uses glucose as source
molecule.
Recent studies on glucose degradation pathways of
malignant tumors also postulate a shunt between the PPP
and the aerobic glycolysis (Embden-Meyerhof-pathway;
EMP) with Glycerinaldehyde-3-phosphate (G3P) possibly
representing the linking molecule between the two.
According to these results G3P is generated from xylose-
5-phosphate (X5P), one endproduct of the PPP by tran-
sketolase like protein 1 (TKTL1). Therefore, TKTL1
could be one of the key enzymes in malignant cell glucose
metabolism [5]. In a recent study we were able to demon-
strate that overexpression of TKTL1 is associated with a
poor outcome in patients with non small cell lung cancer
(NSCLC).
Since TKTL1 is supposed to be a key molecule between
the EMP and the PPP TKTL1 overexpression would
result in high intracellular G3P and pyruvate levels. The
latter would then be either transferred into the TCA or be
catalyzed to lactate by LDH5. In malignant tumors a fair
amount of lactate is produced most probably by LDH5
out of pyruvate [3].
Therefore, we investigated LDH5 expression in non-
small cell lung cancer (NSCLC), its correlation with
TKTL1 and its impact on clinico-pathological parameters
such as tumor stage and survival in a large and well char-
acterized cohort of NSCLC.
Materials and methods
After approval by the ethical committee (No.: 14/04) of
the University of Freiburg and after written informed
consent, 269 patients suffering from non-small cell lung
cancer (NSCLC) were included in this study. Operation
specimens, removed with curative intent between Janu-
ary 1st 1989 and December 31st 2004, were obtained from
the Department of Thoracic Surgery, University Hospital
Freiburg. Pathologic diagnosis and staging was per-
formed at the Institute of Pathology, University Hospital
Freiburg according to the UICC TNM-system, 6th edition
[6]. All specimens were fixed routinely in 4% buffered for-
maline for 24 to 48 h and subsequently paraffin embed-
ded. Reevaluation of the histological diagnosis was
performed by three independent experienced patholo-
gists (G.K., A. z. H. and D. M.).
Tissue microarrays (TMA) of the 269 primary NSCLC
were generated by taking three cores from each tumor
with respect to tumor heterogeneity. A control set of 34
non-neoplastic lung tissues containing alveolar as well as
bronchial areas was also established from tumorfree tis-
sue sample within the same cohort.
The clinico-pathological data of these 269 patients are
summarized in table 1.
Immunohistochemical staining
Three μm thick paraffin sections were taken from all
TMAs and used for immunohistochemistry. After dew-
axing the sections were incubated with TRS (Target
retrieval solution, Dako) for 20 minutes at pH 9 and after-
wards with proteinase K for 5 minutes. The endogenous
avidin-biotin was blocked by the commercial biotin
blocking system (DAKO) for 10 minutes. Subsequently,
the slides were washed in Tris/saline buffer (TBS) twice
and incubated with 1% goat serum for 30 minutes to
block unspecific binding sites. Polyclonal rabbit anti-
LDH5 antibody (ab53010) was applied for 30 min at room
temperature. After rinsing with TBS the slides were incu-
bated with biotinylated anti-rabbit immunoglobulins for
15 minutes at room temperature and treated with
streptavidin-peroxidase (DAKO) for 10 minutes. Staining
was performed by using 3-amino-9-ethylcarbazole (AEC)
substrate and counterstained with hematoxylin (figure 1).
The following evaluation-scoring system was applied: 0
- "negative"; 1 - "weak staining"; 2 - "moderate staining"; 3
- "strong staining". Furthermore the percentage of posi-
tive tumor cells was calculated: For each TMA-core all
malignant cells with nuclear and/or cytoplasmic positiv-
ity for LDH5 were considered in relation to the absolute
number of tumor cells (figure 1).
Upon analysis three cases had to be excluded from the
study as no tumor tissue was present on the immunohis-
tochemically stained sections.
Of 201 tumor samples data for TKTL1 staining was
available.
Statistical analyses
Statistical analysis regarding the correlation of LDH5
expression with clinico-pathological parameters as well
as with the expression of TKTL1 was performed using
the Number Cruncher Statistical System Software release
2007 (NCSS 2007) as well as the SPSS software version 15
for windows for reevaluation of the statistical results. The
analyses included a Pearson-correlation, as well as chi-
square test, Student's t-test, one-way ANOVA, Wilcoxon
Signed Rank test, Kolmogorov-Smirnov test, log-rank
test for Kaplan-Meier survival analysis and multivariate
Cox regression analysis.
Results
LDH5 is overexpressed in malignant neoplastic lung tissue
In none of the 34 non-neoplastic lung tissue samples
LDH5 expression could be detected by immunohis-
tochemistry. In contrast, only 28 cases (10.53%) of all the
NSCLC samples were negative for LDH5 expression.
Approximately 90% of all NSCLC revealed LDH5 expres-
sion. The mean percentage of positive tumor cells within
our collection was 49.44% (+/- 28.62; median: 56.67%)
with a mean staining intensity of 1.28 (+/- 0.81; median:Kayser et al. Diagnostic Pathology 2010, 5:22
http://www.diagnosticpathology.org/content/5/1/22
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Table 1: Summary of the clinico-pathologic data of 269 lung cancer patients
Age 35 - 83 years 63.47 +/- 9.53 years
Number Percent
sex
Male 191 71.0
Female 78 29.0
Histologic entity
Adenocarcinoma
(AC)
90 33.5
Squamous cell carcinoma (SCC) 106 39.4
Large cell carcinoma
(LC)
73 27.1
pT-category
Not assessable 2 0.7
pT1 71 26.4
pT2 147 54.6
pT3 26 9.7
pT4 23 8.6
pN-category
pNx 93 . 3
pN0 147 54.6
pN1 49 18.2Kayser et al. Diagnostic Pathology 2010, 5:22
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1.33). Thus, LDH5 is overexpressed in NSCLC with high
statistical significance compared to non-neoplastic lung
tissue (p < 0,001).
LDH5 shows stronger expression in differentiated NSCLC, 
especially adenocarinomas
Analysis of the three different main entities of non-small
cell lung carcinomas revealed a mean staining intensity of
1.63 +/- 0.86 for adenocarcinomas (AC), 1.12 +/- 0.74 for
squamous cell carcinomas (SCC) and 1.09 +/- 0.81 for
large cell carcinomas (LC) with a mean percentage of
positive tumor cells of 57.35% +/- 28.74 for AC, 44.97% +/
- 27.47 for SCC and 46.35% +/- 28.48 for LC. In a one
sided ANOVA analysis AC revealed a statistically signifi-
cant higher expression than SCC or LC (intensity: p =
0.006; percentage: p < 0.001). Combining the prognostic
favorable ACs with SCCs and comparing their expression
with that of LCs we observed a decrease in the percentage
of positive tumor cells from 50.61% +/- 28.66 for ACs and
SCCs to 46.35% +/- 28.48 for LCs (p = 0.279) and a statis-
tically significant decrease in staining intensity from 1.35
+/- .83 for ACs and SCCs to 1.09 +/- 0.70 for LCs (p =
0.018). No correlation of LDH5 expression could be
detected for histopathologic grading.
LDH5 expression is correlated with mediastinal lymphnode 
metastases and smoking
No statistically significant correlation between LDH5
expression and the individual pT or pN stage could be
detected. Tumors having spread to regional lymphnodes
showed no different LDH5 expression pattern than those
without lymphnode metastases. Comparing the tumors
with no or positive hilar lymphnode metastases (pN0 and
pN1) with those having already spread to mediastinal
lymphnodes (pN2 and pN3) a statistical trend (percent-
age of positive cells) and a statistical significance (staining
intensity) for an increase of LDH5 expression was found
(table 2).
In patients currently smoking or having smoked once
expression of LDH5 measured by staining intensity was
decreased as compared to non-smokers (1.57 +/- 0.83 in
non-smokers vs. 1.24 +/- 0.80 in smokers; p = 0.030; t-
Test).
LDH5 expression correlates positively with TKTL1 
expression
In a linear regression analysis, a positive correlation
between the percentage of positive tumor cells for LDH5
and TKTL1 was found statistically significant (R-squared
= 0.0233; p = 0.0317) meaning a simultaneous increase in
pN2 46 23.0
pN3 20 . 7
UICC
Not assessable 6 2.2
1A 50 18.6
1B 75 27.9
2A 83 . 0
2B 37 13.8
3A 63 23.4
3B 23 8.6
4 72 . 6
Table 1: Summary of the clinico-pathologic data of 269 lung cancer patients (Continued)Kayser et al. Diagnostic Pathology 2010, 5:22
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the percentage of positive tumor cells within our cohort
for TKTL1 and LDH5 expression. For the intensity of
staining no significant correlation between the expression
of the two enzymes could be detected.
Overall survival analysis
The Kaplan-Meier survival analyses for the pT, pN and
UICC-stage is shown in figure 2, figure 3 and figure 4.
In our patient cohort ACs and SCCs had a slightly bet-
ter outcome as compared to LCs (p = 0.28 (Log-Rank)).
Therefore we grouped the two "differentiated" carcinoma
entities into one group which then showed a tendency for
a better survival in comparison to LCs (p = 0.123;
figure 5).
Concerning smoking habits non-smokers had a statisti-
cally significant better outcome than smokers (p = 0.047,
figure 6).
LDH5 overexpression favors a better survival in non-
smokers
Survival analysis comparing LDH5-negative with LDH5-
expressing tumors did not reveal statistical significance (p
= 0.165; figure 7). When defining a cut-off of 50% positive
tumor cells (mean percentage of positive cells 49.44% +/-
28.62) as LDH5 overexpression no difference in survival
was detected, either (p = 0.713). Subdividing the cohort
according to clinico-pathologic parameters into different
prognostically relevant groups (nodal status, UICC-
stages) survival analysis in regard to overexpression of
LDH5 did not reach statistical significance.
In contrast to this, LDH5 overexpression was in favor of
a better prognosis in non-smokers (p = 0.09). This favor-
able effect was not observed in the smokers' group
(figure 8).
Figure 1 Immunohistochemical staining of LDH5 in NSCLC. Upper 
left: Squamous cell carcinoma without immunohistochemically de-
tectable expression of LDH5; Upper right: Adenocarcinoma with weak 
expression of LDH5 - score 1; lower left: Adenocarcinoma with moder-
ate expression of LDH5 - score 2; lower right: Adenocarcinoma with 
strong expression of LDH5 - score 3. (200×)
Table 2: LDH5 expression in correlation with lymphonodal metastasis revealed a statistically significant difference in 
regard to the intensity score between no (pN0) and hilar lymphnode metastases (pN1) and mediastinal lymphnode 
metastases (pN2 and pN3).
pN0 and pN1 pN2 and pN3 p-value
Percentage of positive tumors 
cells
47.12 +/- 29,.3 55.62 +/- 26.33 0.068
Staining intensity 1.22 +/- 0.82 1.43 +/- 0.75 0.036*
* statistically significant (p < 0.05)
Figure 2 Kaplan-Meier survival curve for the separate pT-stages 
(p < 0.001).Kayser et al. Diagnostic Pathology 2010, 5:22
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Discussion
Malignant tumors inhabit a complex carbohydrate
metabolism which differs from that of non-neoplastic
cells with two main paradigms: 1) malignant cells pro-
duce large amounts of lactate even in the presence of suf-
ficient oxygen for aerobic glycolysis [1] 2) intermediates
of the TCA are used for fatty, amino and nucleic acid syn-
thesis [3,4]. Thus, the extensive glucose uptake of cancer
cells is needed not only for energy supply but also to pro-
vide the components for cellular growth and a high
amount of reducing equivalents such as NADPH [3,4]. To
accomplish this, high levels of pyruvate are needed which
can be introduced either into the TCA, converted into
Acetyl-CoA or degraded to lactate by LDH [4,5]. The lat-
ter results in an excess of lactate [3,4]. In concordance
with this theory of changes in tumor cell metabolism
Koukourakis et al. showed that LDH5 was overexpressed
in 36 out of 76 non-small lung cell cancers (47%) [7]. In
Figure 3 Kaplan-Meier survival curve for the separate pN-stages 
(p < 0.001).
Figure 4 Kaplan-Meier survival curve for the separate UICC-stag-
es (p < 0.001).
Figure 5 Kaplan-Meier survival curve in regard to histologic type 
(p = 0.123).
Figure 6 Kaplan-Meier survival curve comparing smokers vs non-
smokers (p = 0.087).Kayser et al. Diagnostic Pathology 2010, 5:22
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our cohort none of the 34 non-neoplastic tissue controls
was positive for LDH5, while 89.43% of tumors were pos-
itive for LDH5. As this is highly statistically significant (p
< 0.001) LDH5 can also be proposed as an immunohis-
tochemical marker for neoplasias in the lung.
LDH is composed of two different subunits, LDH-H
and LDH-M. Each LDH isoenzyme is composed of 4 sub-
units, thus recombination of these subunits leads to 5 dif-
ferent isoenzymes, LDH1 with 4 LDH-H subunits to
LDH5 with 4 LDH-M subunits. These isoenzymes differ
in their specific substrate binding which is highest for lac-
tate in LDH1 and for pyruvate in LDH5, respectively [8].
Maekawa et al. recently reported that the promoter for
the LDHB gene is silenced in cancer cells via hypermeth-
ylation. This leads to restricted transcription of the LDH-
M subunit eliminating transcription of the isoenzyms
LDH1 to LDH4 [9,10]. Upon this pathogenetical back-
ground our results with LDH5 being overexpressed in
NSCLC are in agreement with the proposed tumor biol-
ogy.
We observed decreasing LDH5 expression levels in dif-
ferentiated carcinomas (SCC and AC) compared to LCs.
No correlation between these two subgroups concerning
the percentage of positive cancer cells could be detected.
This suggests that the decrease in staining intensity could
be due to the larger cellular volume in LCs in terms of a
"dilution effect" for staining intensity.
Our cohort of lung cancers showed comparable data in
terms of patients' age, disease stage and survival as pub-
lished in the literature [11-14]. As the patients in our
cohort received primary surgery for curative treatment,
small cell lung carcinomas (SCLC) were not included into
the study due to the small number of available surgical
specimens. At first glance, the frequency of large cell car-
cinomas is relatively high (27.1%). But taking into account
that published data with proportions of around 8 to 10%
for LCs usually include SCLC and rare entities [12],
Figure 7 Kaplan-Meier survival curve for LDH5-positive vs LDH5-
negative tumors (p = 0.165).
Figure 8 Kaplan-Meier survival curve comparing overexpression of LDH5 in smokers (a) (p = 0.16) and non.smokers (b) (p = 0.098).
a) b) Kayser et al. Diagnostic Pathology 2010, 5:22
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adjusting these figures in analogy to our cohort by recal-
culating the percentages without SCLC gives proportions
of around 22% for large cell carcinomas [12]. This is in the
range of our cohort.
Koukourakis et al. reported a link between LHD5 over-
expression and survival in a set of 76 SCCs and 36 ACs
[15]. Taking the same parameters we could not find simi-
lar significant associations, even by omitting LCs and
only investigating ACs and SCCs (figure 9; p = 0.785 for
all NSCLC, p = 0.551 for AC and SCC combined, p =
0.662 for AC, p = 0.145 for SCC). The diversity between
the two studies can be explained not only by the fact that
we used a different antibody but also by the investigated
figures: the median percentage of stained tumor cells was
calculated by 56.67% in our cohort, Koukourakis experi-
enced a median of 80% of cytoplasmatic positive carci-
noma cells. Thus, we were not able to reproduce the cited
results in a large and well characterized cohort of NSCLC
patients.
In order to further analyze the impact of LDH5 expres-
sion on patient's survival a positive correlation only with
advanced (mediastinal) lymphnode metastases (pN0 +
Figure 9 Kaplan-Meier survival curves comparing LDH5 expression according to Koukourakis et al [13]in all NSCLC (p = 0.785) (a), AC com-
bined with SCC (p = 0.551) (b), AC (p = 0.662) (c) and SCC (p = 0.145) (d).
a) b) 
c) d)Kayser et al. Diagnostic Pathology 2010, 5:22
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pN1 vs pN2 + pN3) and a positive correlation between
the expression of LDH5 and TKTL1 was apparent. The
latter is overexpressed in a large portion of NSCLC [16]
and is an independent indicator for aggressive subtypes in
N S C L C ,  a s  w e  h a v e  s h o w n  i n  a n o t h e r  s t u d y .  I t  c o u l d
therefore be discussed if LDH5 overexpression does not
appear as a linear function with a steady increase from lit-
tle to highly aggressive cancers but rather in smaller steps
which then reach a saturation level. Fantin et al. describe
the necessity for upregulation of LDH in cancer cells for
malignant transformation. Their results also stress the
close link between lactate production and oxidative phos-
phorylation. This link is according to their results depen-
dent on the upregulation of LDH but also regulated
through metabolite concentrations [17]. This also sup-
ports our data and hypotheses.
The metabolism of healthy and functionally active cells
is optimized for productivity in terms of fulfilling their
duty to synthesize, degrade, transport or contract. In con-
trast to this, malignant tumor cells do not meet these
demands but only strive for cellular growth and mitosis.
According to this theory high amounts of ATP as
demanded within healthy cells are not only not required
but act contra-productive for the synthesis of basic ele-
ments for cellular growth such as nucleic acids, proteins
and fatty acids. By degradation of pyruvate to lactate the
pool of reductive equivalents on the one hand and the
availability of citric-acid cycle intermediates for fatty and
amino acid synthesis on the other hand is raised [3,4].
Our results which describe the overexpression of LDH5
in tumor cells and its correlation with TKTL1 further
supports this theory of a glucose metabolism optimized
for cellular growth within malignant tumors.
Conclusion
The results of our study indicate that immunohistochem-
ical analysis for LDH5 expression in NSCLC is highly spe-
cific to differentiate malignant neoplasia from healthy
lung tissue. Furthermore, although expression of LDH5
did not directly correlate with patient's survival in our
cohort, significant differences of its expression in correla-
tion with the most indicative prognostic parameter - the
pN stage - was present. This could indicate that the level
of LDH5 expression is of prognostic value in NSCLC. In
this context we could also demonstrate that LDH5
expression was positively correlated with the expression
of TKTL1, which does not only inhabit a close functional
link to LDH5 in the glucose metabolism of malignant
tumors but is also an indicator for aggressive tumor biol-
ogy. As LDH5 plays a pivotal role in tumor glucose
metabolism our data may open new perspectives for
novel chemotherapeutic strategies in NSCLC.
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